Centrex Announces Patent Filings.Business Editors/Health & Medical Writers TULSA, Okla.--(BW HealthWire)--Feb. 13, 2002 Centrex, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CNEX) today announced patent filings in both U.S. and foreign jurisdictions for the nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. sequence detection technology which forms the core of its planned multi-channel biopathogen device. The patents for this unique platform technology were filed through Los Alamos National Laboratory Los Alamos National Laboratory (LANL) (previously known at various times as Site Y, Los Alamos Laboratory, and Los Alamos Scientific Laboratory) is a United States Department of Energy (DOE) national laboratory, managed and operated by Los Alamos National (LANL LANL - Los Alamos National Laboratory, Los Alamos, NM, USA. ) and the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). . The foreign filings were for the European Union and Japan. Centrex owns the exclusive U.S. license to develop, manufacture, and market a system for detecting microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. contamination due to E. coli bacteria, developed at LANL by Dr. Alonso Castro. The detection system, currently in development at LANL, is designed to be adaptable and can be easily tailored to detect a variety of bacterial or viral organisms in real time. Recently, Centrex proposed to LANL that the application of the technology be expanded to detect a variety of potentially lethal biowarfare or bioterrorism agents. Once a Funds-In Agreement has been executed between Centrex and LANL, work can begin on the proposed multi-channel prototype. The organisms being considered for detection by the device include all those named in the biological warfare threat list published by the Defense Intelligence Agency Noun 1. Defense Intelligence Agency - an intelligence agency of the United States in the Department of Defense; is responsible for providing intelligence in support of military planning and operations and weapons acquisition DIA , in addition to several other potential biowarfare agents. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in food, air and water. Centrex, Inc., an Oklahoma Corporation, is a development-stage company organized in 1998 to identify and commercialize proprietary systems for the detection of biological contaminants in food, air and water. For more information, visit the Centrex website at www.centrexcorporation.com, call Investor Relations at 888/492-1257 or James J. Vogle at 561/866-8363. This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion